The importance and efficacy of the co-treatment of allosteric mTOR inhibitors with conventional chemotherapy or with TKI therapy has also been highlighted by Kuwatsuka et al., whose study demonstrated that RAD001 overcame resistance to imatinib by targeting in vitro and in vivo a mostly quiescent Ph+ B-ALL cell subset (CD34+/CD38−) [75]. Here, CD34 is linked to acute lymphoblastic leukemia.